Evidence map›Paper›PMID 35116862›Full record

ArticleTranslational cancer research2019

Efficacy and safety of CalliSpheres

Xia Wu, Shihong Ying, Jing Huang, Changsheng Shi, Jiansong Ji, Zhiyi Peng, Guanhui Zhou, Zhichao Sun, Junhui Sun, Wenqiang Yu and 23 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 1 country.

Xia Wu *Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou 310016, China.
Shihong Ying *Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Jing HuangDepartment of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern Hospital, Ningbo 315040, China.
Changsheng ShiDepartment of Intervention, The Third Affiliated Hospital of Wenzhou Medical University, Ruian 325200, China.
Jiansong JiDepartment of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Zhiyi PengDepartment of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Guanhui ZhouHepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhichao SunDepartment of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.
Junhui SunDepartment of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Wenqiang YuDepartment of Intervention, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
Wenhao HuDepartment of Intervention, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Xin ZhangDepartment of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Jian ZhouDepartment of Radiology, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Guoliang ShaoDepartment of Intervention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Zhihai YuDepartment of Vascular and Interventional Radiology, The Affiliated Hospital of Medical College of Ningbo University, Ningbo 315020, China.
Qinming HouDepartment of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's Hospital, Hangzhou 310023, China.
Wenjiang GuDepartment of Intervention, Jiaxing Second Hospital, Jiaxing 314099, China.
Tiefeng LiDepartment of Radiology, Beilun District People's Hospital of Ningbo, Ningbo 315800, China.
Xiaoxi XieInterventional Center, Xinchang People's Hospital, Shaoxing 312500, China.
Guohong CaoDepartment of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University International Hospital, Hangzhou 310000, China.
Haijun DuDepartment of Intervention, Dong Yang People's Hospital, Dongyang 322100, China.
Dedong ZhuDepartment of Liver Oncology, Ningbo No.2 Hospital, Ningbo 315010, China.
Huanhai XuDivision of Digestive Endoscopy, Yueqing City People's Hospital, Yueqing 325600, China.
Jun HanDepartment of Intervention, Jiaxing First Hospital, Jiaxing 314033, China.
Wenbin JiDepartment of Radiology, Taizhou Hospital of Zhejiang Province, Linhai 317000, China.
Jian FangDepartment of Hepatobiliary Surgery, Quzhou People's Hospital, Quzhou 324000, China.
Ling LiDepartment of Liver Oncology, Ningbo No.2 Hospital, Ningbo 315010, China.
Jiaping ZhengDepartment of Intervention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Jun LuoDepartment of Intervention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Yutang ChenDepartment of Intervention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Tingyang HuDepartment of Intervention, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
Hongjie HuDepartment of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou 310016, China.
Xiaohua GuoDepartment of Intervention, Jinhua Central Hospital, Jinhua 321000, China.
Zhejiang University · CNSir Run Run Shaw Hospital · CNNingbo Medical Center Lihuili Hospital · CNRuian People's Hospital · CNWenzhou Medical University · CNZhejiang Provincial People's Hospital · CNFirst Affiliated Hospital of Wenzhou Medical University · CNQuzhou City People's Hospital · CNZhejiang Chinese Medical University · CNZhejiang Taizhou Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to assess the treatment response, short-term overall survival (OS) and safety profiles of drug-eluting beads transarterial chemoembolization (DEB-TACE) in patients with secondary liver cancer.

methodsFifty-five patients with secondary liver cancer underwent DEB-TACE were enrolled in this prospective cohort study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST). OS was calculated from the time of DEB-TACE operation until the date of death.

resultsThe complete response (CR) and objective response rate (ORR) at 1-3 months post DEB-TACE were 12.7% and 67.3%. Mean OS was 383 d (95% CI: 360-406), and 6-month OS rate was 93.4%±3.7%. Subgroup analysis revealed previous conventional TACE (cTACE) treatment was correlated with worse ORR (P=0.028), and it was a risk factor for ORR achievement (P=0.021). As for liver function, the percentages of abnormal TP (P=0.031), TBIL (P=0.022), ALT (P=0.002) and AST (P=0.035) were increased at 1 week post DEB-TACE compared to baseline, while these four indexes returned to baseline (all P>0.05) at 1-3 months post DEB-TACE. As to safety profiles, 41 (66.1%), 28 (45.2%), 17 (27.4%), 8 (12.9%) and 6 (9.7%) cases had pain, vomiting, fever, nausea and other adverse events (AEs) respectively during DEB-TACE operation, while 26 (41.9%), 9 (14.5%), 8 (12.9%), 4 (6.5%), 1 (1.6%) and 2 (3.2%) cases had pain, fever, vomiting, nausea, bone marrow toxicity and other AEs respectively at 1 month after DEB-TACE operation.

conclusionsDEB-TACE was efficient and well tolerated in treating patients with secondary liver cancer.

Indexed as

Drug-eluting beads transarterial chemoembolization (DEB-TACE)liver functionoverall survivalsafetysecondary liver cancertreatment response

Identifiers

PMID35116862
PMCPMC8797412
OpenAlexW4254633864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.